ZVRA Q4 2025 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

$618M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$34M+183.4% YoY

Gross Profit

$33M96.5% margin

Operating Income

$9M27.3% margin

Net Income

$12M35.6% margin

EPS (Diluted)

$0.20

QoQ Revenue Growth

+30.9%

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$6M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$285M

Total Liabilities

$130M

Stockholders' Equity

$155M

Cash & Equivalents

$62M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$34M	$12M	+183.4%
Gross Profit	$33M	$11M	+208.3%
Operating Income	$9M	-$15M	+160.4%
Net Income	$12M	-$36M	+134.0%